CClinicalTrials.gg
CompletedNCT05314413Updated Nov 25, 2024

Examining Sex-based Differences in Metabolic and Mechanistic Responses to Disuse Induced Muscle Atrophy

An interventional study of Single Leg Immobilization in Muscle Atrophy and Muscle Disuse Atrophy, sponsored by McGill University. Completed at 1 site in Canada. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-25.

Sponsored by McGill University · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 35 Years
Sex
All
01

Study summary

The purpose of the proposed research is to define whether there are differences between females and males (i.e. sex-based differences) in the metabolic and mechanistic regulation of disuse-induced muscle atrophy in vivo in humans.

Read the detailed description

Patients in rehabilitation may undergo periods of prolonged limb immobilization in response to injury, surgery, or illness. Due to disuse, the size and strength of muscles controlling the affected limb can decrease significantly, resulting in physical impairment or lower quality of life during the recovery phase. When measured as maximal isometric contraction, muscle strength in the immobilized limb decreases at a dramatic rate, around 1.0-1.2%/day. These declines in muscle size and strength may vary between sexes - this remains unclear. Muscle atrophy is thought to be caused by a significant decline in muscle protein synthesis (the main pathway attributing to muscle growth/ hypertrophy). There are also various pathways by which muscle is broken down. It is the sex-based differences in this muscle protein synthesis rate of decline and the pathway by which muscle is broken down that we would like to investigate for their contribution to muscle size and strength decline after a period of immobilization.

The purpose of the proposed research is to define whether there are differences between females and males (i.e. sex-based differences) in the metabolic and mechanistic regulation of disuse-induced muscle atrophy in vivo in humans.

On the participant's first visit, prior to beginning the study (Day 0), they will be instructed to fill out a health-related questionnaire, screened for all anthropometric characteristics (height, weight, age, sex) and undergo a DXA scan for body composition details. They will be familiarized with all study procedures including the muscle biopsies, strength tests, D2O, diet and exercise recording. They will also be fitted for the immobilization brace. The leg that will be immobilized will be randomized in each participant. This first visit will last approximately 2 hours. When participants return on Day 1 of the study, they will first have a lower-body MRI scan done. Following this, participants will perform single-leg strength tests on the Biodex. Thereafter on Day 2, venous blood draws and saliva samples will be taken. Participants will be administered their loading dose of D2O (5mL·kg body mass-1 of 70% D2O) and provided with daily maintenance doses of 50mL of D2O to continue to take each day for the duration of the experiment. Upon returning for Day 3, participants will undergo a single skeletal muscle biopsy from the vastus lateralis of one leg. Participants will repeat their blood and saliva sample on this day. Participants will then be outfitted with the knee brace and crutches prior to leaving the facility. Participants will also be outfitted with an ActiGraph activity monitor to record physical activity and energy expenditure while they are immobilized for 7 days. This third visit will last approximately 3 hours. Participants will monitor their own dietary intake via diet recording, which they will be instructed to carry out for 2 weekdays (i.e. Monday - Friday) and one weekend day (i.e. Saturday, Sunday). During the 7-day period of immobilization, participants will provide a saliva sample every day for measurement of 2H enrichment in body water. The saliva samples should be taken in the morning right after the participants wake up and before any food intake. Participants should drink the 1 × 50 mL maintenance dose of D2O per day provided right after collecting their saliva samples. On Day 8 participants will return to the facility to undergo post-immobilization testing which will include: a DXA scan, a lower-body MRI, two skeletal muscle biopsies (one in each leg), a blood sample, a saliva sample, and single-leg strength tests on both legs. This final visit will last approximately 4 hours.

02

Conditions studied

  • Muscle Atrophy
  • Muscle Disuse Atrophy

Keywords

  • Immobilization
03

In context

Muscular Disorders, Atrophic

51 studies on the registry are indexed under Muscular Disorders, Atrophic; 11 are open to participants now.

This study's enrollment of 24 is close to the median of 24 across 48 interventional studies indexed under Muscular Disorders, Atrophic.

Browse Muscular Disorders, Atrophic studies →

Lead sponsor

McGill University is the lead sponsor of 244 studies on the registry; 49 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Aged between 18-35 years inclusive
  • Healthy, recreationally active (active for >5 hours/ week)
  • Having given informed consent

Exclusion criteria

Exclusion Criteria:

  • Type I or Type II diabetes
  • Highly trained (active for > 15 hours/week)
  • Lower limb and/or back injuries in the last 6 months
  • A history of thrombosis / cardiovascular disease
  • Use of anticoagulants
  • Musculoskeletal / orthopedic disorders
  • Use of tobacco products
  • Using medications known to modulate skeletal muscle metabolism including corticosteroids, hormone replacement therapy (HRT), non-steroidal anti-inflammatory drugs (i.e. paracetamol) and over-the-counter supplements including protein powder, creatine monohydrate, and fish oil
  • Pregnant
  • Currently participating in another clinical trial/ physical intervention research study
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Single Leg Immobilization - Males

    Males will be subjected to 7-days of single-leg immobilization.

    Procedure: Single Leg Immobilization

  • Experimental
    Single Leg Immobilization - Females

    Females will be subjected to 7-days of single-leg immobilization.

    Procedure: Single Leg Immobilization

Interventions

  • ProcedureSingle Leg Immobilization

    7-days of single leg immobilization to induce muscle atrophy

06

What researchers measure

Primary outcomes

  1. Fractional muscle protein synthesis rate

    Integrative fractional muscle protein synthesis rates in the immobilized and non-immobilized leg

    Time frame: Integrative fractional muscle protein synthesis rates over 7 days

Secondary outcomes

  1. Muscle size

    Changes in muscle size, measured pre and post immobilization

    Time frame: Baseline and 7 days

  2. Muscle strength

    Changes in muscle strength, measured pre and post immobilization

    Time frame: Baseline and 7 days

  3. mRNA expression

    Changes in mRNA gene expression of specific biomarkers pertaining to skeletal muscle atrophy, measured pre and post immobilization

    Time frame: Baseline and 7 days

  4. Protein abundance and phosphorylation

    Changes in protein abundance and phosphorylation status of select proteins involved in muscle protein synthesis and breakdown, measured pre and post immobilization

    Time frame: Baseline and 7 days

07

Study locations

1 site
  • Currie Gynasium 309 - McGill University
    Montréal, Quebec H2W 1S4, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05314413
Lead sponsor
McGill University
Responsible party
Tyler Churchward-Venne (Principal Investigator, McGill University) — Principal investigator
First posted
Apr 6, 2022
Start date
Nov 1, 2022
Primary completion
Nov 15, 2024
Completion
Nov 15, 2024
Last update
Nov 25, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion